Articles from THL Partners

PaveMasters, a leading provider of pavement maintenance services across the Western United States, today announced a majority investment from THL Partners (“THL”), a premier private equity firm investing in middle market growth companies. Existing investor Northern Lakes Capital (“NLC”) has sold its ownership stake as part of the transaction. With the backing of THL, PaveMasters will build on the company's founding strategy to create the preeminent destination for high-quality asphalt maintenance operators in the Western U.S.

THL Partners ("THL"), a premier private equity firm investing in middle-market growth companies, today announced the successful completion of its sale of AMI, a global leader in firmware and platform management solutions, to Lattice Semiconductor (NASDAQ: LSCC). As part of the transaction, THL will retain an equity ownership interest in Lattice Semiconductor.

THL Partners, a premier private equity firm investing in middle-market growth companies, today announced the final close of THL Equity Fund X, L.P. (“Fund X”) with $6.35 billion in investable capital.

Celerion, a global leader in clinical pharmacology and bioanalytical sciences, today announced a majority investment from THL Partners (“THL”), a premier private equity firm investing in middle market growth companies. The investment will support Celerion’s continued growth and innovation, including expanding its clinical and bioanalytical capabilities and advancing its work to help pharmaceutical and biotechnology partners bring new therapies to patients worldwide.

THL Partners (“THL”), a premier private equity firm investing in middle market growth companies, today announced the entry into a definitive agreement to acquire Headlands Research (“Headlands” or “the Company”), a leading multinational network of clinical trial sites, from funds managed by leading global investment firm KKR. The strategic partnership between THL and Headlands will fuel Headlands’ continued expansion, enhance its technology and centralized infrastructure, and further strengthen its ability to deliver high-quality, diverse clinical trial data for pharmaceutical and biotech sponsors in support of Headlands’ mission to improve lives by advancing innovative medical therapies.